2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 721

T Cell Activation Induces Increased mRNA Expression Of The Splicing Factor SF2/ASF But Simultaneous Protein Downregulation Via Proteasome Mediated Degradation
Abstract Number: 2301

T Cell Proliferative Response To Type II Collagen In Patients With Rheumatoid Arthritis
Abstract Number: 1621

T Helper 17 Cells and Interferon Type I: Partners In Crime In SLE?
Abstract Number: 338

Tailored Approach To Early Psoriatic Arthritis Patients: Ultrasonographic Predictors For Structural Joint Damage
Abstract Number: 1193

Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Abstract Number: 1862

Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Abstract Number: 2743

Targeted Activation Of The Metabolic Super-Regulator AMP-Activated Protein Kinase (AMPK) Blunts Gouty Inflammation
Abstract Number: 2400

Targeted Exon Resequencing For Korean Rheumatoid Arthritis
Abstract Number: 949

Targeting CD1c-Expressing Mdcs To Inhibit Tcell Activation and Thymus and Activation Regulated Chemokine (TARC)-Dependent Chemotaxis In RA
Abstract Number: 41

Targeting Cereblon With The High Affinity Immunomodulatory Compound CC-220: A Novel Therapeutic Agent For Autoimmunity
Abstract Number: 2234

Targeting Therapy Of Citrullinated Antigen-Specific B Cells Ameliorates Collagen-Induced Arthritis
Abstract Number: 798

Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study
Abstract Number: 983

Teaching Musculoskeletal Care Through An Inter-Disciplinary and Inter-Professional Clinical Training Program Successfully Provides Trainees With Knowledge and Skills Required To Deliver Excellent Musculoskeletal Care
Abstract Number: 194

Team Managed Care From a Patient’s Perspective: A Study Of Biological Patients At a Canadian Centre
Abstract Number: 2791

Telephone Consultation Usage In a Pediatric Rheumatology Clinic: Considerations In Optimizing Nursing Resources

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].